APPLICATION
ANDA077035
TYPE
ANDA
ORIGINAL APPROVAL
2004-10-28
LATEST ACTION
2024-11-25
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued
Products
CITALOPRAM HYDROBROMIDEDiscontinued
CITALOPRAM HYDROBROMIDE EQ 20MG BASE · TABLET · ORAL
CITALOPRAM HYDROBROMIDEDiscontinued
CITALOPRAM HYDROBROMIDE EQ 40MG BASE · TABLET · ORAL
CITALOPRAM HYDROBROMIDEDiscontinued
CITALOPRAM HYDROBROMIDE EQ 10MG BASE · TABLET · ORAL
Approval history
2024-11-25Labeling · Supplement 12 · standardAP
2024-11-25Labeling · Supplement 13 · standardAP
2013-03-28Labeling · Supplement 11 · standardAP
2012-12-18Labeling · Supplement 10 · standardAP
2009-09-28Labeling · Supplement 9AP
2007-10-19Labeling · Supplement 8AP
2007-10-19Labeling · Supplement 6AP
2005-08-01Labeling · Supplement 5AP
2005-05-11Labeling · Supplement 4AP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.